The purpose of the Biostatistics Core is to provide professional expertise in biostatistics and bioinformatics for all Breast Cancer SPORE projects, investigators, and participants. Functions provided by this core include development of experimental designs, power analysis, and sample size estimation;data quality control statistical/bioinformatic analysis and interpretation of findings;and collaboration on presentation of results. To achieve these functions, the core director and core members are constantly available to investigators, and are in regular contact with project and core leaders. The primary objectives ofthe Biostatistics Core are: 1. To provide study design and review all laboratory, animal, and clinical studies including feasibility assessment, power analysis, and sample size estimation 2. To collaborate in project data analysis, interpretation of results, and the writing of final study reports and manuscripts 3. To work with the Pathology &Tissue Informatics Core and Imaging Core in the development of research project databases, to maintain data quality control and to ensure timely data capture 4. To develop and evaluate statistical/bioinformatic methods for experimental design and data analysis Biostatistics Core support is required in all Breast Cancer SPORE studies. Core personnel have worked and will continue to work closely with project leaders to ensure the core provides state-of-the-art statistical/bioinformatic support.
The relevance of the Biostatistics Core lies in our provision of services essential for the conduct of high-quality collaborative breast cancer research;sound statistical/bioinformatics inputs are critical throughout the lifespan of a research project, from conception to completion.
|Williams, Michelle M; Lee, Linus; Hicks, Donna J et al. (2017) Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Mol Cancer Res 15:259-268|
|Zhao, Bin; Sensintaffar, John; Bian, Zhiguo et al. (2017) Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin. Bioorg Med Chem 25:3087-3092|
|Williams, Michelle M; Vaught, David B; Joly, Meghan Morrison et al. (2017) ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. Breast Cancer Res 19:105|
|Jansen, Valerie M; Bhola, Neil E; Bauer, Joshua A et al. (2017) Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res 77:2488-2499|
|Mayer, Ingrid A; Abramson, Vandana G; Formisano, Luigi et al. (2017) A Phase Ib Study of Alpelisib (BYL719), a PI3K?-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer. Clin Cancer Res 23:26-34|
|Jovanovi?, Bojana; Mayer, Ingrid A; Mayer, Erica L et al. (2017) A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Clin Cancer Res 23:4035-4045|
|Hanker, Ariella B; Garrett, Joan T; Estrada, Mónica Valeria et al. (2017) HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clin Cancer Res 23:4323-4334|
|Morrison Joly, Meghan; Williams, Michelle M; Hicks, Donna J et al. (2017) Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res 19:74|
|Lee, Kyung-Min; Giltnane, Jennifer M; Balko, Justin M et al. (2017) MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab 26:633-647.e7|
|Guerrero-Zotano, Angel L; Arteaga, Carlos L (2017) Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. Cancer Discov 7:561-574|
Showing the most recent 10 out of 327 publications